{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:28:25Z","timestamp":1769603305916,"version":"3.49.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The multicenter, prospective phase 2 Australasian Leukaemia &amp; Lymphoma Group NHL29 trial was conducted to assess the addition of ibrutinib to R-mini-CHOP (dose attenuated R-CHOP; rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients aged \u226575 years with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Treatment consisted of six 21-day cycles of ibrutinib\u2013R-mini-CHOP followed by two 21-day cycles of R-ibrutinib. Coprimary end points were deliverability and 2-year overall survival (OS). The median average relative total dose and average relative dose intensity for the entire regimen were both 97% (interquartile range, 82-100 and 88-100, respectively). With a median follow-up of 35.5\u00a0months, the 2-year OS was 68% (95% confidence interval [CI], 55.6-77.4) with a 2-year progression-free survival (PFS) of 60.0% (95%\u00a0CI, 47.7-70.3). Median OS and PFS were 72\u00a0months (95%\u00a0CI, 35 to not reached) and 40\u00a0months (95%\u00a0CI, 20.4 to not reached), respectively. The overall response rate was 76% (61\/79) of patients, with a complete response rate of 71% (56\/79). Deaths occurred in 34 of 79 patients (43%), including 17 from progressive disease and 5 treatment related. Overall, 67% patients experienced at least 1 serious adverse event. Most common adverse events were infections and diarrhea (the majority grade 1-2). In both health-related quality of life measures, there was an improvement in functional and symptom scales, median health state classification score, and median visual analogue scale in responders over time. In conclusion, this study showed that the addition of ibrutinib to R-mini-CHOP was both deliverable and efficacious in elderly DLBCL patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014035","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T15:36:41Z","timestamp":1730475401000},"page":"5674-5682","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4945-2574","authenticated-orcid":false,"given":"Emma","family":"Verner","sequence":"first","affiliation":[{"name":"1Department of Haematology, Concord Repatriation General Hospital, NSW, Australia"},{"name":"2Faculty of Medicine & Health, The University of Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Johnston","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine & Health, The University of Sydney, NSW, Australia"},{"name":"3Department of Haematology, Westmead Hospital, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7448-7294","authenticated-orcid":false,"given":"Nalini","family":"Pati","sequence":"additional","affiliation":[{"name":"4Department of Haematology, The Canberra Hospital, ACT, Australia"},{"name":"5School of Medicine & Psychology, Australian National University, ACT, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[{"name":"6Department of Oncology, Eastern Health, VIC, Australia"},{"name":"7Olivia Newton-John Cancer Research Institute at Austin Health, VIC, Australia"},{"name":"8School of Public Health and Preventive Medicine, Monash University, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Peng","family":"Lee","sequence":"additional","affiliation":[{"name":"9Department of Haematology, Flinders Medical Centre, SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-1399","authenticated-orcid":false,"given":"Tara","family":"Cochrane","sequence":"additional","affiliation":[{"name":"10Department of Haematology, Gold Coast University Hospital, QLD, Australia"},{"name":"11School of Medicine and Dentistry, Griffiths University, QLD, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Yoon","family":"Cheah","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Sir Charles Gairdner Hospital, WA, Australia"},{"name":"13Department of Haematology, PathWest Laboratory Medicine, WA, Australia"},{"name":"14Faculty of Health & Medical Sciences, The University of Western Australia, WA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Filshie","sequence":"additional","affiliation":[{"name":"15Department of Haematology, St Vincent\u2019s Hospital, VIC, Australia"},{"name":"16Faculty of Medicine, Dentisty & Health Sciences, The University of Melbourne, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0408-8455","authenticated-orcid":false,"given":"Duncan","family":"Purtill","sequence":"additional","affiliation":[{"name":"13Department of Haematology, PathWest Laboratory Medicine, WA, Australia"},{"name":"17Department of Haematology, Fiona Stanley Hospital, WA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanlon","family":"Sia","sequence":"additional","affiliation":[{"name":"18Department of Haematology, Tweed Valley Hospital, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8069-090X","authenticated-orcid":false,"given":"Anoop K.","family":"Enjeti","sequence":"additional","affiliation":[{"name":"19Department of Haematology, Calvary Mater Hospital, NSW, Australia"},{"name":"20School of Medicine & Public Health, The University of Newcastle, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-8943","authenticated-orcid":false,"given":"Christina","family":"Brown","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine & Health, The University of Sydney, NSW, Australia"},{"name":"21Institute of Haematology, Royal Prince Alfred Hospital, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Murphy","sequence":"additional","affiliation":[{"name":"22Department of Haematology, Royal Hobart Hospital, TAS, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0569-2873","authenticated-orcid":false,"given":"Jennifer","family":"Curnow","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine & Health, The University of Sydney, NSW, Australia"},{"name":"3Department of Haematology, Westmead Hospital, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Lee","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Concord Repatriation General Hospital, NSW, Australia"},{"name":"2Faculty of Medicine & Health, The University of Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1000-5393","authenticated-orcid":false,"given":"Maher K.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"23Mater Research Institute, The University of Queensland, QLD, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mannu","family":"Walia","sequence":"additional","affiliation":[{"name":"24Australasian Leukaemia & Lymphoma Group, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1415-4065","authenticated-orcid":false,"given":"Belinda E.","family":"Butcher","sequence":"additional","affiliation":[{"name":"25WriteSource Medical Pty Ltd, NSW, Australia"},{"name":"26School of Biomedical Sciences, University of New South Wales, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Concord Repatriation General Hospital, NSW, Australia"},{"name":"2Faculty of Medicine & Health, The University of Sydney, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"issue":"1","key":"2024111214260997000_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"2024111214260997000_bib2","first-page":"379","article-title":"Original article: non-Hodgkin\u2019s lymphoma in the elderly: a study of 602 patients aged 70 or older from a Danish population-based registry","volume":"3 (5)","author":"d\u2019Amore","year":"1992","journal-title":"Ann Oncol"},{"issue":"2","key":"2024111214260997000_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2141.2011.08934.x","article-title":"Analysis of very elderly (\u226580 years) non-Hodgkin lymphoma: impact of functional status and co-morbidities on outcome","volume":"156","author":"Nabhan","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"2024111214260997000_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2024111214260997000_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-136511","article-title":"Final analysis of the international double-blind randomized phase III study of lenalidomide maintenance in elderly patients with DLBCL in response after R-CHOP, the Remarc Study from Lysa","volume":"136","author":"Thieblemont","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2024111214260997000_bib6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024111214260997000_bib7","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(16)30171-5","article-title":"Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group","volume":"4","author":"Peyrade","year":"2017","journal-title":"Lancet Haematol"},{"issue":"1","key":"2024111214260997000_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jgo.2019.06.020","article-title":"Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi","volume":"11","author":"Merli","year":"2020","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"11","key":"2024111214260997000_bib9","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1200\/JCO.20.02666","article-title":"Subcutaneous rituximab-miniCHOP compared with subcutaneous rituximab-miniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older","volume":"39","author":"Oberic","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2024111214260997000_bib10","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024111214260997000_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2024111214260997000_bib12","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2024111214260997000_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","article-title":"Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP","volume":"87","author":"Bosly","year":"2008","journal-title":"Ann Hematol"},{"issue":"1","key":"2024111214260997000_bib14","first-page":"65","article-title":"Average relative dose intensity and the impact on design of clinical trials","volume":"14","author":"Hryniuk","year":"1987","journal-title":"Semin Oncol"},{"issue":"27","key":"2024111214260997000_bib15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024111214260997000_bib16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ajh.27151","article-title":"R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: a propensity matched population-based study","volume":"99","author":"Al-Sarayfi","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"2024111214260997000_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41416-021-01525-4","article-title":"Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year real world data of practice patterns and outcomes in England","volume":"126","author":"Hounsome","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"2024111214260997000_bib18","doi-asserted-by":"crossref","first-page":"Cns51","DOI":"10.2217\/cns-2019-0022","article-title":"Ibrutinib in primary central nervous system diffuse large B-cell lymphoma","volume":"9","author":"T Low","year":"2020","journal-title":"CNS Oncol"},{"issue":"2","key":"2024111214260997000_bib19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.14218","article-title":"Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome","volume":"179","author":"Mason","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"2024111214260997000_bib20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024111214260997000_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hon.3081","article-title":"The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi","volume":"41","author":"Cencini","year":"2023","journal-title":"Hematol Oncol"},{"issue":"22","key":"2024111214260997000_bib22","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/bloodadvances.2021004777","article-title":"A\u00a0simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL","volume":"5","author":"Isaksen","year":"2021","journal-title":"Blood Adv"},{"issue":"44","key":"2024111214260997000_bib23","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.18632\/oncotarget.27785","article-title":"Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine","volume":"11","author":"Lodhi","year":"2020","journal-title":"Oncotarget"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/21\/5674\/2312538\/blooda_adv-2024-014035-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/21\/5674\/2312538\/blooda_adv-2024-014035-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T14:26:28Z","timestamp":1731421588000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/21\/5674\/517656\/Ibrutinib-plus-rituximab-and-mini-CHOP-in-older"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":23,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,11,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014035","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}